Patent ID: 9000031
Filing Date: 2015-04-07
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition comprising: a) a therapeutically effective amount of a thioxanthone-based autophagy inhibitor; b) a therapeutically effective amount of a cancer therapeutic autophagy inducing compound; and c) a pharmaceutically acceptable carrier, wherein the thioxanthone-based autophagy inhibitor is 1-((2(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one, 1-(2-diethylaminoethylamino)-4-(hydroxymethyl)-9-thioxanthenone, N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thiaxanthen-4-yl]methyl]methanesulfonamide, indazole analogues thereof, or salts thereof, and wherein the cancer therapeutic autophagy inducing compound is an arsenic trioxide, an etoposide, a rapamycin, a histone deacetylase inhibitor, a tyrosine kinase inhibitor, a tamoxifen, a temozolomide, an imatinib, or a bortezomib.